Research Report - 2001

Ludwik Hirszfeld Institute of Immunology and Experimental Therapy
Polish Academy of Sciences

Rudolfa Weigla 12, 53-114 Wrocław


Research Report – 2001


Head: Professor Czesław Ługowski, Ph.D.

Laboratory of Microbial Immunochemistry and Vaccines
Head: Professor Czesław Ługowski, Ph.D.
Biochemical characteristics of macromolecules involved in immunological processes – immunochemical studies of bacterial endotoxins

The aim of our studies in the year 2001 was the immunochemical characterization of endotoxins - lipopolysaccharides, major surface antigens and important virulence factors of Gram-negative bacteria. Endotoxins were isolated from opportunistic pathogens such as Hafnia alvei, and Citrobacter gillenii.

By utilizing two-dimensional NMR spectroscopy in conjunction with chemical and immunological methods, we have established the structures of H. alvei O-specific polysaccharides present in the strains PCM 1196 and PCM 1223. An acidic O-specific polysaccharide isolated from strain 1196 is consists of pentasaccharide repeating units containing hexoses, N-acetylhexosamines and C-4 substituted galacturonic acid. O-antigen of H. alvei strain 1223 is a neutral a -mannan composed of pentasaccharide repeating units. Immunoblotting showed a strong cross-reactivity between the investigated LPS and the LPS of E. coli O9 and K. pneumoniae O3. The serological relationship of the LPSs of these bacteria is due to the structural identity of their O-specific polysaccharides, though the LPSs differ in their core regions. A neutral O-specific polysaccharide isolated from the LPS of C. gillenii strain 1544 was studied by specific degradations and chemical and instrumental analyses. It is composed of neutral, tetrasaccharide repeating units substituted with O-acetyl groups on C-2 of b-L-rhamnose residues. (In collaboration with the N.D. Zielinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, the Russian Federation).

Laboratory of Glycoconjugate Immunochemistry
Head: Associate Professor Hubert Krotkiewski, Ph.D.
Immunochemical and genetic studies on human glycophorin and other proteins active in the immune system

During the last years we have investigated the presence of the blood-group ABH antigens in human glycophorin A (in collaboration with prof. Bo Nilsson, Umea, Sweden); this year we analyzed N-glycans of GPA, originating from blood group O erythrocytes. Using ES mass spectrometry of permethylated oligosaccharide alditols, native and desialylated, we confirmed the presence of blood group H antigen in these N-glycans: it resides on one branch of the N-glycan, while the other is sialylated. Studies like these are important in view of the emerging knowledge on the role of GPA as a marker of glycosylation changes under pathological conditions.

This year we participated in the 4th Int. Workshop on Monoclonal Antibodies Against Human Red Blood Cells and Related Antigens. The aim of our studies was to investigate the specificity of the monoclonal antibodies against human glycophorin A (GPA) and C (GPC), against variant glycophorin Mia, and against Duffy antigen. The general method we used was Pepscan-analysis, which is based on the chemical synthesis of defined short peptides on plastic pins and determining the reactivity of the antibodies using the ELISA method. We identified 10 peptidic epitopes of a defined sequence.

We also investigated the polyagglutination of the NOR erythrocytes by antibodies, commonly present in human sera. We found that a neutral glycosphingolipid fraction from NOR erythrocytes inhibited this polyagglutination. Using ES mass spectrometry (in collaboration with Dr. V. Reinhold, New Hampshire, USA), we isolated and analyzed the structure of a neutral glycosphingolipid from NOR erythrocytes, which was shown to be a1-4 galactosylated globoside (Gala 1-4GalNAcb1-3Gala 1-4Galb1-4Glc-Cer). This is a new carbohydrate structure, never before described. We also found extended neutral glycosphingolipid in NOR erythrocytes (Gala 1-4GalNAcb1-3Gala 1-4GalNAcb 1-3Gala1-4Galb1-4Glc-Cer).

Laboratory of General Immunochemistry
Head: Associate Professor Maria Janusz, Ph.D.
Natural Immunomodulators - ColostrininÒ, a proline-rich polypeptide (PRP) complex from ovine colostrum

A proline-rich polypeptide (PRP) complex was isolated in our Laboratory by Janusz et al.(1974) from ovine colostrum. The polypeptide complex shows immunoregulatory and procognitive activities. PRP, in the form of orally administered tablets called Colostrinin Ò (containing 100 mg PRP), improves the outcome of Alzheimer’s disease (AD) patients and prevents further deterioration of their health status.

The mechanism of action of ColostrininÒ in AD patients is not yet fully clarified. Recently, the involvement of the immune system in the pathogenesis of AD and the role of cytokines in the regulation of neurodegenerative processes have been recognized. Other factors which can affect the development of AD are oxidative stress and an overproduction of nitric oxide (NO).

We have found that ColostrininÒ may regulate the secretion of an array of cytokines in cultures of human blood cells and that it inhibits overproduction of NO and superoxide anion (O2-) in murine macrophages. The results obtained suggest that the beneficial effects of Colostrinin Ò in AD patients might be caused, among others, by its regulatory effects on cytokine secretion and its inhibition of an overproduction of reactive oxygen radicals and NO.

Laboratory of Glycobiology
Head:Professor Maciej Ugorski, Ph.D.
Tumor-associated antigens, sialosyl-Lewisa and CEA, as targets in gene anticancer therapy

In our studies on new carriers for gene transfer, the effect of surface charge on the association of liposomes with human colon CX-1 cancer cells was analyzed. When phospatidylserine was incorporated into a lipid bilayer, the amount of liposomes associated with cells tended to increase along with the amount of negatively charged lipid present in the liposomal lipid bilayer. When the cationic lipid dioleyol-1,2-diacyl-3-trimethylammonium-propane (DOTAP) was included in the liposome formula, uptake by the cells was also increased. Maximum binding occurred when the amount of positively charged lipids in liposomes was about 10 mol% of lipids.

The condensation of chemically well-defined DNA plasmids was studied by the use of fluorescence correlation spectroscopy (FCS). It became clear that the DNA molecule exhibits discrete conformational change between the coil and globule states with the addition of a small amount (the order of magnitude being 10-5 M) of cationic surfactants, such as spermine and hexadecyltrimethyl ammonium bromide (HTAB).

Head: Professor Michał Zimecki, Ph.D.

Laboratory of Immunobiology
Head: Professor Michał Zimecki, Ph.D.
Studies on the mechanism of action of synthetic and natural immunomodulators of potential application in prevention and therapy

Studies on the role of lactoferrin (LF) in immune response were continued. We demonstrated that a receptor, exhibiting affinity to mannose, plays a critical role in the mediation of the regulatory activity of LF in cellular immune response in mice. Other studies in vitro revealed that LF regulated the proliferative response of mononuclear blood cells to phytohemagglutinin (PHA) and mixed lymphocyte reaction. The first clinical trial on patients, subjected to minor surgery, showed that LF given per os before operation enhanced the response of mononuclear blood cells to PHA and lipopolysaccharide.

Other studies demonstrated immunosuppressory activities of Vratizolin®, a registered antiviral drug, in several models in vivo and in vitro, in both mice and humans. Interesting, was the differential action of cyclosporine A on the generation of humoral and cellular immune responses in mice, which were also described.

Other investigations involved the immunotropic properties of 10 derivatives of 5-amino-3-methylizoxazolo-4 carboxyl acid hydrazide in models of humoral and cellular immune response in mice.

Studies were also conducted on the mechanism of bone formation by injection of Hela cells into the thigh muscles of mice. We proved that the induction of bone formation was conditioned by the secretion of bone morphogenic proteins by the grafted cells.

Laboratory of Immunopharmacology
Head: Associate Professor Stanisław Szymaniec, M.D.
New synthetic and natural compounds of potential antiinflammatory and immunotropic activity

The biological activity of lipopolysaccharide (LPS) containing sphingosine was investigated in the rat model of experimental induced uveitis (EIU). A glucose-nonfermenting Gram-negative strain was isolated from a routinely disinfected bronchofiberoscope. LPS isolated from the bacterial mass contained sphingosine, a rare component in bacteria compared with those typically occuring in LPS (Department of Immunology of Infectious Disease, Institute of Immunology and Experimental Therapy).

The LPS isolated from the clinical strain was twice as active in EIU induction as that from Shigella sonnei Phase I and Escherichia coli K12 strains. Polymyxin B (PmB) did not inhibit the EIU induced by this LPS, in contrast to the complete inhibition of Eschericha coli K12 lipopolysaccharide activity by PmB. The results indicate that the LPS from the investigated clinical isolate has potent endotoxic activity. The structural difference of lipid A in the LPS containing sphingosine may be responsible for the lack of inhibitory effect of Polymyxin B.

A series of new nociceptin analogues containing cysteine (synthesized by Dr H. Bartosz-Bechowski, Wroclaw University) was tested for their nociceptive effects in tail-flick tests on 129/Iiw strain female mice after icv (intracerebroventricular) injection. The cysteines were introduced in order to get irreversibly binding analogues, based on the assumption that the cysteines in the ligand can interact with those from the receptor to form S-S bridges. In vivo tests revealed that Cys1-nociceptin (1-13)-NH2 (Cys1-NC) is an antagonist, whereas Cys7-NC is an agonist. Gly1,[Phe(p-NO2)]4-NC was less active, indicating that the antagonist properties of Cys1-NC are associated with the presence of the sulfhydryl group of cysteine. The analogues D-Cys2 and Cys3 were also almost inactive.

Laboratory of Immunopathology
Head: Professor Irena Frydecka, M.D.
The mechanisms of immune deficiency in neoplastic diseases

Several mechanisms have been suggested to account for the poor immune response of T lymphocytes in B chronic lymphocytic leukemia (B-CLL). Recently, there has been increasing interest in costimulatory and inhibitory regulators of immune activation, in particular in the CD28 homologue CTLA-4 (CD152) molecule, which is transiently expressed on T lymphocytes after activation.

We evaluated the kinetics and levels of expression of down-regulatory CTLA-4 and costimulatory CD28 molecule on peripheral blood T lymphocytes stimulated with anti-CD3+rIL-2. There were different kinetics and levels of T-cell CTLA-4 expression in healthy controls and B-CLL patients. The percentage of CD3+/CTLA-4+ cells among the unstimulated cells of all the persons studied was negligible. The highest percentages of CD3+/CTLA-4+ cells were obtained in normal subjects after 72 h and in B-CLL patients after 24 h of stimulation. The mean percentage of CD3+/CTLA-4+ cells returned to undetectable levels after 72 h of stimulation in the control group and after 120 h of stimulation in B-CLL patients. There was a statistically higher percentage of CD3+/CTLA-4+cells in B-CLL patients at each time point tested compared with the control group. There was also a statistically lower percentage of CD3+/CD28+ cells in B-CLL patients compared with the controls.

Our study provided evidence of different kinetics, increased CTLA-4 and decreased CD28 expression on peripheral blood T lymphocytes in B-CLL, which, in consequence, may result in a stronger, earlier and longer-lasting down-regulation of T-cell activation and may be one of the mechanisms of immunological impairment in this disease.

We also studied the expression of the universal cdk inhibitor p27KIP1 in B-CLL. This protein was present in nearly 100% of lymphocytes in all B-CLL populations tested. Its cellular content, estimated semi-quantitatively by specific mean fluorescence intensity (MIF) and the percentage of p27+/CD19+/CD5+ cells, was significantly higher in B-CLL patients than in the control group. There was no correlation between the level of p27 expression and clinical stage of the disease. Apoptosis of neoplastic cells, estimated by the TUNNEL method, did not correlate with p27 expression.

Head: Professor Jolanta Zakrzewska-Czerwińska, Ph.D.

Laboratory of the Molecular Biology of Microorganisms
Head: Professor Jolanta Zakrzewska-Czerwińska, Ph.D.
The molecular basis of replication and gene expression and the designing of compounds inhibiting these processes

Initiation of Helicobacter pylori chromosome replication. The sequence analysis of the H. pylori genome revealed a few surprising features: (i) the typical eubacterial block of replication genes, dnaA-dnaN-recF-gyrB, does not exist; (ii) an origin of DNA replication is not evident from the genome sequence; (iii) the dnaC gene encoding DnaC protein that delivers the DnaB helicase to the prepriming complex is absent. We charecterized the key elements of the initiation of H. pylori chromosome replication: DnaA protein and a putative oriC region. The H. pylori oriC region containing five DnaA boxes was cloned as an autonomously replicating minichromosome.

The interactions between DnaA protein and the oriC region were analyzed by competition gel retardation assay. The H. pylori DnaA protein shows an interesting DNA binding feature: being a protein of rather low sequence specificity it forms nucleoprotein complexes preferentially with the H. pylori oriC region.

Type II thioesterase from Streptomyces coelicolor A3(2). Many type I polyketide synthases (PKS) clusters contain additional TE genes located adjacent to PKS genes. These are discrete proteins called type II thioesterases (TE II) to distinguish them from the chain-terminating thioesterase domains, (TE I), which are usually fused to the terminal PKS module. A gene of a new, type II thioesterase, scoT, associated with the cluster of putative type I polyketide synthase genes from Streptomyces coelicolor A3(2) was found. When expressed in a heterologous host, Streptomyces fradiae, scoT successfully complemented the resident TE II gene (tylO) and proved to be catalytically equivalent to the TylO protein.

Laboratory of Signaling Proteins Head: Associate Professor Wojciech Gorczyca, Ph.D. Function and physicochemical properties of proteins involved in Ca2+ -dependent signal transmission by cAMP and cGMP in cells of the immune system

The intracellular level of cyclic GMP (cGMP) depends on the activity of opposite enzymes: guanylyl cyclases (GC), which synthesize the nucleotide from GTP, and phosphodiesterases (PDE), which hydrolyze it to GMP.

Two distinct forms of guanylyl cyclases (GC), particulate (pGC) and soluble (sGC), have been recognized in vertebrates. They differ in structure, subcellular localization, and mechanism of activation. The aim of our studies was to determine which form of GC is responsible for cGMP synthesis in cells of mouse lymphatic organs. Using known activators of pGCs (ANP, BNP, STa) and sGC (SNP), we found that although both forms of GCs contributed to cGMP synthesis in the thymus, lymph nodes, and spleen, the activity of soluble GC was markedly higher.

Continued studies on the mechanisms that regulate the metabolism of cGMP in rat macrophages showed that the activity of pGC in the cells depends on environmental conditions and can be modulated by other intracellular signaling pathways. Since phosphodiesterases (PDEs) belonging to seven different families are able to hydrolyze cGMP, we asked which of them might be responsible for the nucleotide degradation in macrophages. We found that in rat macrophages at least three isoforms of PDEs are possibly involved in cGMP hydrolysis. Detailed studies are in progress to determine which of these are in fact expressed in the cells.

Head: Professor Andrzej Lange, M.D.

Laboratory of Clinical Immunology
Head: Professor Andrzej Lange, M.D., Professor
Genetical aspects and pathomorphology of alloreactivity in patients receiving allogeneic stem cell transplantation

Allogeneic stem cell transplantation is performed across the barrier of histocompatibility antigens. In family HLA matched transplantation, the difference between the recipient and donor depends rather on minor than on major HLA specificities. In alternative donor transplantation, genetic difference is apparent in one haplotype in family setting and in both haplotypes in unrelated donors transplantation. Therefore, in a group of transplanted patients there are a variety of individuals with different degrees of incompatibility in histocompatibility specificities. This was investigated with the use of DNA techniques which describe the specificities at a high resolution. A limit of permissive incompatibility was assesed by following the fates of patients transplanted with the use of manipulated (elutriation for T cell depletion) and unmanipulated grafting material. For immunological outcome, probably the most important cytokine is IFN-gamma. Cytokine genes are polymorphic, and we documented an association between the risk of aGvHD and IFN-gamma gene polyumorphism.

The outcome of transplantation with a given extent of HLA compatibility largely depends on the number of CD34+ cells transplanted. It was shown that the contribution of CD34+CXCR4- cells to the PBPC was positive correlated with the yield of hematopoietic progenitors mobilization to the blood. The architecture of the marrow was investigated in some detail by immunostaining trephine biopsy specimens taken from cadaveric organ donors. It was found that the reactive nodules in the marrow were organized according to the interaction of CXCR3 and CXCR4 with their respective ligands.

Laboratory of Immunogenetics
Head: Associate Professor Piotr Kuśnierczyk, Ph.D.
The role of HLA region in susceptibility to psoriasis

This work was done in collaboration with the Clinic of Dermatology and Venerology, Medical University of Wrocław (Prof. F. Wąsik, Prof. E. Baran, Prof. M. Cisło, and Dr. P. Nockowski).

Psoriasis vulgaris is the only human disease associated with HLA-C. The association of the HLA-Cw*0602 allele with this condition was described for many populations, but to varying degree, from strong to almost negligible. In addition, it is still not known whether it is the HLA-C gene itself or rather a closely linked gene that is causatively linked with psoriasis. Several genes from this region were examined in addition to HLA-C and -B. However, HLA-linked complement component polymorphic genes were not studied extensively. Therefore, we typed 67 psoriatic patients for alleles of the HLA-linked complement components BF, C4A and C4B. Alleles of C3, encoded on another chromosome, were established in parallel as a negative control. The frequencies in patients were compared with those in unrelated healthy controls: 100 individuals for C4A and C4B, 890 for BF, and 4719 for C3. We found no association of BF alleles with disease, nor of C3. Among the C4 alleles, C4B*3 was present in 13.4% of patients as compared with 1% of controls (OR, 15.36; 95% CI, 1.897 to 124.42; p=0.0009), and C4A*6 was present in 19.4% of patients versus 7% of controls (OR, 3.20; 95% CI, 1.202 to 8.508; p=0.0155). The high frequency of C4B*3 in psoriatics has not been described so far. These results suggest a contribution of C4 genes themselves or a closely linked gene to the susceptibility to psoriasis (Cisło et al., Immunol. Letters, 2001, 80,

In last years we have described a new B lymphoblastoid cell line (B-LCL), HAJ, that did not express HLA class II antigens HLA-DR, -DQ and –DP, although the genes for these molecules were present (Mańczak et al., Arch. Immunol. Ther. Exp., 1996, 44, 171-178; Kość et al., Centr. Europ. J. Immunol., 1998, 23, 26-29). Here, we examined the effect of interferong, a potent stimulator of HLA gene expression, on HLA class I and class II expression on HAJ cells. We found that culture of HAJ cells in the presence of interferon g upregulated HLA class I expression that was otherwise much lower than on B-LCLs without the HLA defect. However, interferon g did not restore HLA class II expresssion on HAJ cells, similar to its lack of effect on bare lymphocyte syndrome-derived B-LCLs and bare lymphocyte syndrome-like B-LCL mutants (Nowak et al., Arch. Immunol. Ther. Exp., 2001, 49, 453-460).

Head: Professor Andrzej Górski, M.D.

Laboratory of Bacteriophages
Acting head: Assistant Professor Beata Weber-Dąbrowska, Ph.D.
Bacteriophages provide regulatory signals in mitogen-induced murine splenocyte proliferation

Extensive studies on phage therapy were continued in 2001. Specific phages were applied in 341 patients with different suppurative infections caused by multi-drug-resistant bacteria. The majority of infections were long persisting ones and antibiotic therapy had failed. Phage therapy was found to be highly effective in 81% of cases.

Bacteriophage treatment was also performed in 20 cancer patients with solid tumor and hematological malignances. Recovery from infections was achieved in all cases.

In addition, the bacterial flora of the posterior laryngeal wall, larynx and surgical wounds of the patients treated surgically for carcinoma of the larynx was investigated. A similarity of some bacterial strains isolated from various habitats was demonstrated by comparing the biochemical characteristics, drug resistance patterns, and susceptibility to bacteriocins and bacteriophages. Bacteriophagotyping confirmed the similarity of rods belonging to the genera Enterobacter and Pseudomonas.

Laboratory of Reproductive Immunology
Acting head: Assistant Professor Małgorzata Jerzak, M.D.
Immunological aspects of reproduction failures

Apoptosis has been proposed as a mechanism for maintaining immune privilege. Expression of Fas ligand (FasL) by the human trophoblast has been recently accepted as a mechanism providing protection against the lytic action of activated decidual immune cells. Transient expression of extracellular matrix (ECM) proteins reflects trophoblast differentiation. Therefore, the purpose of the study was to determine the role in pregnancy maintenance of T-cell apoptosis in an ECM environment in women with a history of recurrent spontaneous abortion (RSA). We studied the apoptosis of peripheral blood T cells after culture with mAb OKT-3 alone and with mAb OKT-3 and the following ECM: fibronectin and collagen IV in 10 women with a history of RSA, examined before and during pregnancy, and in 10 normal, healthy women with previous successful pregnancy outcome. We used Cell Death Detection ELISA (Boehringer Mannheim), a photometric enzyme immunoassay for the quantitative in vitro determination of cytoplasmic histone-associated DNA fragments after induced cell death. In addition, the apoptosis of T cells isolated from the decidua of women with subsequent pregnancy failure was studied. Cells undergoing DNA fragmentation were identified by DNA analysis using flow cytometry. This method was based on the accumulation of ethanol-fixed apoptotic cells in the sub-G0/G1 peak of the DNA content as a result of the loss of DNA fragments from the cells and because of the reduced ability of DAN to be stained by propidium iodide. The highest values of enrichment factor, i.e. mU of the sample (dying/dead cells) per mU of the corresponding control (viable cells), were observed after peripheral T-cell culture with fibronectin in samples of women with subsequent pregnancy success. The apoptotic index (the percentage of positive cells per total number of cells) of decidual T cells was lowest in women with a history of recurrent spontaneous abortion compared with women after sporadic or elective abortion. Apoptosis of activated maternal immune cells in the human decidua may be a defense mechanism against rejection of the fetal allograft by the maternal immune system. Preliminary data suggest that disturbances in the programmed cell death of activated T cells in the human decidua can be responsible for recurrent pregnancy loss. Therefore, the apoptosis of activated cytotoxic T cells might be an interesting possible explanation of successful pregnancy outcome.

1,25-Dihydroxyvitamin D3 induces differentiation and inhibits proliferation of human promyelocytic leukemia cells. PD 98059, the specific inhibitor of MEK1 and MEK2, was found to inhibit D3-induced monocytic differentiation of HL-60 cells. This finding proves that activation of the raf/MEK1,2/erk1,2 signal transduction pathway is essential for monocytic differentiation of human leukemia cells. On the other hand, inhibition of cytosolic phospholipase A2 accelerated differentiation of HL-60 cells induced by D3, suggesting the possible existence of a feedback loop between extracellular-signal regulated kinases and phospholipase A2. PRI-1906, an analog of vitamin D2, and PRI-2191, an analog of vitamin D3, bind the nuclear vitamin D receptor (nVDR) with substantially lower affinity than D3, but retain a higher differentiation-inducing activity, as estimated in a HL-60 leukemia-cell model. To examine how their increased differentiation-inducing activity is regulated, we tested the hypothesis that membrane-mediated events, unrelated to nVDR, are necessary for differentiation in response to PRI-1906 and PRI-2191. Induction of leukemia-cell differentiation in response to analogs of vitamin D was inhibited by LY294002 (PI 3-K inhibitor), PD98059 and rapamycin (p70S6K inhibitor), indicating that activation of signal transduction pathways unrelated to nVDR is necessary for differentiation.

Laboratory of Tissue Immunology
Acting head: Assistant Professor Beata Nowakowska, Ph.D.
Minor histocompatibility antigen HA-1 polymorphism in the Polish population

Among the five non-sex-linked minor histocompatibility antigens, a recipient's disparity for HA-1 is associated with the occurrence of grades II-IV acute GvHD. HA-1 antigen is a nonapeptide encoded by a gene designated as KIAA0223 located on chromosome 19. HLA-A*0201 molecules have high affinity for the HA-1H peptide, and this complex is recognized by HA-1-specific cytotoxic T cells. The HLA-A*0201/HA-1R complex does not generate a detectable immune response.

In our study we determined the allele frequency of HA-1 in 58 unrelated HLA-A*0201 individuals from the south-western area of Poland. The HA-1H allele frequency was 0.405 and that of HA-1R 0.595. The genotype distribution was: homozygotes H/H 14% and R/R 33%, heterozygote H/R 53%. The distribution of HA-1 alleles and genotypes fits well with the distribution expected under Hardy-Weinberg equilibrium (c 2 =0.668).

Genetic factors associated with increased risk for cancer: the p53 Arg/Pro polymor-phism at codon 72


The p53 Arg/Pro polymorphism at codon 72 (CGC vs. CCC) is in a proline-rich functional domain (aa 64-92) necessary for efficient growth suppression. It has been suggested to be involved in susceptibility to various types of cancers. To examine whether it could represent a risk factor in the Polish population, we analyzed exon 4 codon 72 in constitutional DNA.

The frequency of p53 Pro allele was 0.276, compared with 0.29 to 0.35 reported for Caucasians in general. The genotype distribution was: Pro – 0.054, Arg – 0.503 and Pro/Arg – 0.443. A similar distribution was observed in cancer patients with familial cancer history. In patients with multiple primary neoplasms, no Pro genotype was found, and the frequencies of Arg and Pro/Arg were 0.482 and 0.519, respectively. In pediatric neoplastic and non-neoplastic patients, the respective frequencies of Pro allele were 0.285 and 0.352. In both these groups, the respective genotype patterns were as follows: Pro: 0.1 and 0.11, Arg: 0.53 and 0.47, Pro/Arg: 0.37 and 0.482.

Laboratory of Virology
Head: Professor Zofia Błach-Olszewska, Ph.D.
Study of non-specific immunity in viral infection

We found that murine resident peritoneal cells exhibit innate antiviral immunity. During in vitro culture of the cells for several days, this type of immunity was gradually reduced. As the viruses VSV, EMCV, HSV-1 belong to different taxonomic groups, the immunity expressed by the leukocytes appears to be non-specific. Cyclosporine A, given to BALB/c mice, reduced the innate antiviral immunity in the mice.

Viral and bacterial infections are among the risk factors for the vertical transmission of HIV. Therefore, the effect of experimental double infection with unrelated viruses (VSV and EMCV) and the effect of VSV and sonicated treponema pallidum or bacterial LPS on innate antiviral immunity was studied. A reduction of the innate immunity of placenta and amniotic membrane by the agents was observed, which may contribute to an increased vertical transmission of viruses.

The effect of paramyxovirus (NDV) on the nitric oxide (NO) production by pulmonary leukocytes was studied on the bronchial asthma model. Paramyxovirus enhanced NO production in pulmonary leukocytes, mainly in neutrophils, in the cases of overlapping, mixed airway infections coexisting with bronchial asthma.

Acid-labile IFN levels in sera from HIV-infected patients were measured. The correlations with clinical status and standard diagnostic parameters were analyzed. In the case of patients on HAART therapy, acid-labile IFN was usually absent. Therefore, a high level of IFN suggests unsuccessful therapy.

The antiviral properties of organoselenium compounds, analogs of ebselen, were determined using EMCV, VSV and HSV-1 viruses. Virucidal activity against EMCV and HSV-1 was shown for ebselen and several of its derivatives. Some of them were able to reduce VSV replication in human cord blood leukocytes.

Antiviral activity of free and immobilized photosensitizers was studied in culture medium and in the presece of red blood cell concentrate. The enveloped viruses (HSV-1 and VSV) were photoinactivated by some of the compounds. However, there was no activity against EMCV, a non-enveloped virus.

Laboratory of Cellular Interactions
Head: Associate Professor Danuta Duś, Ph.D.
The interaction of tumor cells with endothelium involving constituents of the immune system in the neoplastic process



The organ specific phenotype of endothelial cells influences cell trafficking and extravasation. A necessary step of the extravasation process are the adhesive interactions of endothelial cell adhesion molecules with their ligands, presented by a partner cell surface molecules. In our previous study we demonstrated that the acquisiton of tissue specific high metastatic phenotype by several selected variants LS-180 human colon carcinoma cells was accompanied by an increased expression of glycosylated tumor antigens, which correlated with their differential adhesion pattern to endothelial cells.

The studies in 2001 concerned endothelial cells phenotypic characteristics which determine the organ specificity of metastatic secondary growth. The subject of the study was a panel of eight human endothelial cell lines from distinct tissue origin that we immortalized and characterized (Patent No. 99 16169, 21/12/99, CNRS, France). Their organ specificity was confirmed by the differential display of endogenous lectins and cytokine receptors, as well as tissue specific addressins and other adhesion molecules expression (Kieda et al., Endothelium, in press). In collaboration with the group of Prof. S. Szala from the Institute of Oncology in Gliwice, two of the endothelial cell lines were examined for the presence of KDR/flk-1 gene promoter, specific for endothelial cells. It was revealed that the promoter was present in some tumors, i.e. human ovary carcinoma and in mouse sarcoma, which makes it a candidate for use in antitumor gene therapy (Szary J. et al., Anticancer Res.).

Head: Associate Professor Andrzej Gamian, Ph.D.

Laboratory of Medical Microbiology
Head: Associate Professor Andrzej Gamian, Ph.D.
The pathogenesis of some autoimmune diseases of bacterial etiology: the role of sialic acid, glycolipids, endotoxins and bacterial proteins

The current activity of this laboratory is focused on studies of the mechanisms of pathogenicity in autoimmune diseases with bacterial etiology, the role of molecular mimicry, bacterial proteins in pathogenicity, and the structures and functions of bacterial capsular antigens and endotoxins (Post. Hig. Med. Dośw., 2001, 55, 211-232).

The general strategy for the elaboration of protective tools against invading bacteria involves determining the structures of the molecules involved in infection and immune processes and understanding their biological activities. Thus, the structures of several such antigens have been established (Carbohydr. Res., 2001, 330, 523-528 and 331, 331-336, FEMS Immunol. Med. Microbiol., 2001, 30, 223-227).Sialic acid is one of the key molecules on the surface of tissue cells participating in immunological functions. In some bacteria, sialic acid may be a constituent of its surface antigens, and the occurrence of sialic acid is associated with an increased pathogenicity of the bacteria, particularly as it is involved in autoimmune processes. Sialic acid is structurally similar to 3-deoxy-octulosonic acid, an inherent component of endotoxin. Thus, the interference of these bacterial components with the functions of tissue sialic acid may contribute to the mechanisms of pathogenicity (FEMS Immunol. Med. Microbiol., 2001, 31, 169-173). Due to the structural mimicry of sialic acid-containing structures, care should be taken when antibacterial vaccines are constructed to avoid the induction of autoantibodies.

Acting head: Associate Professor Leon Strządała, Ph.D.

Laboratory of Tumor Immunology
Acting Head: Associate Professor Adam Opolski, Ph.D.
Studies onthe mechanisms of tumor progression, metastasis and on the effects of experimental antitumor therapy

Studies on the effects of experimental antitumor immunogenotherapy have been performed. After multiple peritumoral injections of IL-2-producing plasmocytoma cells into C38 colon cancer-bearing mice, an increase of NO production in tumor tissue, correlating with significant therapeutic effect was observed.

In the search for models allowing study of the pathogenesis of metastasis, tumor angiogenesis, and the effectiveness of antitumor and antiangiogenic (genistein) treatment we have been shown that: 1) The distribution of experimental tumor metastases depends on the route of tumor cells inoculation. 2) Genistein inhibits the proliferation in vitro of all mouse tumor cell lines applied, but its activity in vivo is differential and depends on the tumor type and on the route of tumor cells transplantation. 3) The antimetastatic effect of genistein in mice which have undergone surgical removal of a primary tumor depends on the histological type of cancer. 4) The influence of genistein on the antitumor effect of cyclophosphamide depends on the route of tumor cells transplantation and on the histological type of cancer.

An original model to determine the amount of blood in the tumor tissue, corresponding to the degree of its vascularization was established. The results obtained in this model (I125-labeled mouse albumin) did not differ from those obtained with the use of the referential technique applying FITC-dextran.

A new original procedure for the conjugation of antitumor drugs with macromolecular carriers was elaborated. The procedure was tested for synthesis of the following conjugates: BSA-tomudex, BSA-methotrexate, immunoglobulins-antitumor drugs, fibrinogen-fluorescein-antitumor drugs, and lysozyme-haptens.

Laboratory of Cellular Immunology
Head: Associate Professor Leon Strządała, Ph.D.
Normal and pathological development and selection of lymphoid and neuronal cells

We have been searching for novel thymus-specific genes and proteins that change their expression during the intrathymic development of T lymphocytes. The identification, characterization and functional analysis of such genes and proteins may contribute to a better understanding of the processes that are central to the function of the immune system, such as the generation and selection of the self MHC-restricted and self tolerant repertoire of T-cell receptor specificities. Using such techniques as cDNA-RDA (Representational Difference Analysis) and ‘cDNA microarrays’, we have identified a number of new thymocyte-specific sequences that are currently under investigation.

Cell lines derived from fetal mouse brain were established in our laboratory. The cells were characterized with the use of antibodies against beta-tubulin III (neuronal marker) and GFAP (marker of astroglial cells) and visualized with the use of immunofluorescent confocal microscopy. Preliminary experiments using dual-labeled cells showed that beta-tubulin III and GFAP were expressed in the same cells. A panel of neuronal and glia markers (nestin, MAP2, neurofilaments, beta-tubulin III, Gap43, p75NTR, and GFAP) are currently under investigation using the RT-PCR technique.

Publikacje - 2001 r.

Prace oryginalne opublikowane:

  1. Adamus G., Mańczak M., Machnicki M.: Expression of CC chemokines and their receptors in the eye in autoimmune anterior uveitis associated with EAE. Invest. Opth. Vis. Sci, 2001, 42, 2894-2903 (IF-4.373)
  2. Baczyńska D., Widerak K., Ugorski M., Langner M.: Surface charge on the association of liposomes with colon carcinoma cells. Z. Naturforsch., 2001, 56, 872-877 (IF-0.709)
  3. Bartosz-Bechowski H., Międzybrodzki R., Szymaniec S.: Novel nociceptin analogues. Acta Biochim. Pol., 2001, 48(4), 1155-1158 (IF-0.749)
  4. Bilińska M., Frydecka I., Podemski R., Teodorowska R., Gruszka E.: Expression of Fas antigen on T cell subpopulation in peripheral blood of patients with relapsing-remitting multiple sclerosis. Med. Sci. Monit., 2001, 7, 251-255
  5. Bilińska M., Frydecka I., Podemski R.: Przebieg kliniczny a stężenie rozpuszczalnego receptora interleukiny-2 i rozpuszczalnej formy międzykomókowej cząsteczki adhezyjnej (ICAM-1) w surowicy krwi w stwardnieniu rozsianym. Neur. Neurochir. Pol., 2001, 35, 47-55.
  6. Bogunia-Kubik K., Polak M., Lange A.: TNF-alpha and TNF-beta polymorphic features associate with toxic complications in patients after allogeneic hematopoietic stem cell transplantation. W: Proceedings of the "European Federation of Immunological Societies - EFIS 2000" (Poznań, Poland, September, 23-27, 2000), eds. Mackiewicz A., Kurpisz M., Żeromski J., publ., Monduzzi Editore, Bologna (Włochy), 2001, 211-217
  7. Bogunia-Kubik K., Tomeczko J., Suchnicki K., Lange A.: HLA-DRB1*03, DRB1*11 or DRB1*12 and their respective DRB3 specificities in clinical variants of sarcoidosis. Tissue Antigens, 2001, 57, 87-90 (IF-2.305)
  8. Chełmońska-Soyta A., Kątska L., Kurpisz M., Stefaniak T., Zimecki M.: The effect of Ureaplasma diversum activated mononuclear leukocytes on the development and interferon-t production by bovine IVF-derived embryos. J. Reproductive Immunol., 2001, 51, 145-158 (IF-1.771)
  9. Chełmońska-Soyta A., Zimecki M., Nowacki W., Nikołajczuk M.: Differential effects of heparin on NO and tumor necrosis-alpha production in bovine mononuclear cells stimulated with Salmonella typhimurium lipopolisaccharide. Comparative Immunol. Microbiol. Infectious Diseases, 2001, 24, 151-164 (IF-0.902)
  10. Chen V., Halverson K., Waśniowska K., Lisowska E., Chen J., Moulds M., Reid M. E.: Direct evidence for the existence of Miltenbergera antigen. Vox. Sang. 2001, 80, 230-233 (IF–2.067)
  11. Daroszewski J., Bolanowski M., Gamian A., Rybka J., Spring A.: The use of glycosamino-glycan excretion measurements in the assessment of organic complications in acromegaly. Endokrynologia Polska – Pol. J. Endocrinology, 2001, 52, 347-352
  12. Dawiskiba J., Zimecki M., Kwiatkowska D., Kuźmiński A.: The effects of endotoxin administration on cytokine production in obstructive jaundice rats. Arch. Immunol. Ther. Exp., 2001, 49, 391-397
  13. Duk M., Reinhold B. B., Reinhold V. N., Kuśnierz-Alejska G., Lisowska E.: Structure of a neutral glycosphingolipid recognized by human antibodies in polyagglutinable erythro-cytes of the rare NOR phenotype. J. Biol. Chem. 2001, 276, 40574-40582 (IF–7.368)
  14. Frydecka I., Boćko D., Kosmaczewska A., Ciszak L., Morilla R.: The effect of peripheral blood lymphocytes stimulation on zeta chain expression and IL-2 production in Hodgkin’s disease. Brit. J. Cancer, 2001, 84 (10), 1339-1343 (IF-3.489)
  15. Frydecka I., Wołowiec D., Kapelko-Słowik K., Potoczek S., Kuliczkowski K.: Stężenie rozpuszczalnych form cząsteczek adhezyjnych ICAM-1 (sICAM-1) i selektyny E (s-selektyna E) w surowicy krwi chorych na chłoniaki złośliwe nieziarnicze w różnych fazach choroby. Adv. Clin. Exp. Med., 2001, 10, 151-155
  16. Górski A., Kasprzycka M., Nowaczyk M., Wieczorek Z., Siemion I.Z., Szelejewski W., Kutner A.: Cyclolinopeptide: a novel immunosuppressive agent with potential anti-lipe-mic activity. Transpl. Proc., 2001, 33, 553 (IF-0.678)
  17. Grabas K., Kołwzan B., Czarny A., Pawełczyk A., Stolarski M.: Effect of phenoma in granular active carbon beds on the drinking water’s health wuality. Ed. Prof. H. Górecki, Czech-Pol Trade, Praha, Brussels, Stockholm. “Chemistry for Agriculture”, vol. 2, ”Pollution control in agriculture and fertilizer industry”, 2001, 288-297.
  18. Grabas K., Kołwzan B., Czarny A., Pawełczyk A., Stolarski M.: Wpływ zjawisk zachodzących w złożach granulowanych węgli aktywowanych na jakość zdrowotną wody do picia. I Sympozjum Centrum Biomonitoringu, Biotechnologii i Ochrony Ekosystemu Dolnego Śląska. Red. H. Górecki, M. Kochman, A. Ożykow, J. Zurodniak. Oficyna Wydawnicza Pol. Wrocł., 2001, 33-45
  19. Grieb P., Kamienowski J., Janisz M., Kuśnierczyk P., Kawiak J., Hoser G., Chrapusta S.: Hematological effects of intermittent 2-hour infusions of cladribine (CdA) in multiple sclerosis patients: a comparison of two dosage patterns. Int. J. Hematol., 2001, 74 (4), 421-427 (IF-1.212)
  20. Hume A. N., Collinson L. M., Rapak A., Gomes A. Q., Hopkins C. R., Seabra M. C.: Rab27a regulates the peripheral distribution of melanosomes in melanocytes. J. Cell Biol., 2001, 152, 795-808 (IF-13.955)
  21. Indrova M, Bubenik J, Simova J, Bieblova J, Jandlova T, Smahel M, Vonka V, Glazman-Kusnierczyk H, Pajtasz-Piasecka E, Radzikowski C, Mikyskova R.: Chemoim-munotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. Oncol. Rep, 2001, 8, 1371-1374 (IF-1.290)
  22. Jatczak B., Gejdel E., Pająk J., Podwińska J., Błach-Olszewska Z.: Study on risk factors for transplacental viral infections: effect of bacterial factors and double viral infections on virus replication in placenta and amniotic membranes. Placenta, 2001, 22, 360-371 (IF-2.101)
  23. Jerzak M., Górski A.: T cell adhesion to extracellular matrix proteins in women with unexplained infertility. Proceedings of the „European Federation of Immunological Societies-EFIS 2000”, Monduzzi Editore, Bologna, 2001, 707-711
  24. Katzenellenbogen E., Kocharova N.A., Zatonsky G.V., Kübler-Kiełb J., Gamian A., Shashkov A.S., Knirel Y.A., Romanowska E.: Structural and serological studies on Hafnia alvei O-specific polysaccharide of a-D-mannan type isolated from the lipopolysaccharide of strain PCM 1223. FEMS Immunol. Med. Microbiol., 2001, 30, 223-227 (IF-1.075)
  25. Katzenellenbogen E., Zatonsky G.V., Kocharova N.A., Rowiński S., Gamian A., Shashkov A.S., Romanowska E., Knirel Y.A.: Structure of the O-specific polysaccharide of Hafnia alvei PCM 1196. Carbohydr. Res., 2001, 330, 523-528 (IF-1.354)
  26. Kraj P., Pacholczyk R., Ignatowicz H., Kisielow P., Jensen P., Ignatowicz L.: Positive selection of CD4+ T cells is induced in vivo by agonist and inhibited by antagonist peptides. J. Exp. Med., 2001, 194(4), 407-416 (IF-15.236)
  27. Krajewski K., Lisowski M., Wieczorek Z., Siemion I.Z.: Pro-pro amide bond configura-tion and the immunosuppressive activity of cyclolinopeptide A. Polish J. Chem., 2001, 75, 1441-1448 (IF-0.575)
  28. Kruzel M.L., Janusz M., Lisowski J., Fischleigh R.V., Georgiades J.A.: Toward an understanding of biological role of colostrinin peptides. J. Molec. Neuroscience, 2001, 17, 379-389 (IF-1.765)
  29. Krzyżanowska D., Ożyhar A., Lalik A., Rodriguez-Parkitna J.M., Szkudlarek J., Waśniowska K., Lisowska E., Kochman M.: Juvenile hormon binding protein and transferrin from Galleria mellonella share a similar structural motif. Biol. Chem., 2001, 382, 1027-1037 (IF–2.97)
  30. Kübler-Kiełb J., Zatonsky G.V., Katzenellenbogen E., Kocharova N.A., Szostko B., Gamian A., Shashkov A.S., Knirel Y.A.: Structure of the O-specific polysaccharide isolated from the lipopolysaccharide of Citrobacter gillenii serotype O12a, 12b strain PCM 1544. Carbohydr. Res., 2001, 331, 331-336 (IF-1.354)
  31. Lange A., Dłubek D., Lange J.: Anti-T-lymphocyte globulin in conditioning of hemato-poietic stem cell transplantation in aplastic anemias in children. W: Lectures to the Second ATG-Fresenius-Satellite-Symposium, wyd. Fresenius HemoCare, Germany, 2001, 10-17
  32. Lange A., Grzywacz B., Łaba A.: Reminiscences from the Central East European Workshop on HLA. EFI Newsletter, 2001, 34, 9
  33. Laskowska, A., Dolińska-Krajewska, B., Zabel, M., Ugorski, M.: Sialosyl Lea-carrying gangliosides present on the surface of colon carcinoma cells are not directly involved in their adhesion to E-selectin. Eur. J. Cell Biol., 2001, 80, 784-791 (IF-2.801)
  34. Lewandowicz-Uszyńska A., Medyńska A., Cembrzyńska-Nowak M., Zwolińska D.: Zdolność do produkcji tlenku azotu przez leukocyty pełnej krwi u dzieci chorych na nawracające zakażenia układu moczowego. Pol. Merk. Lek., 2001, 58, 241-243
  35. Lorenc-Kubis I., Kowalska J., Pochroń B., Żużło A., Wilusz T.: Isolation and amino acid sequence of a serine proteinase inhibitor from common flax (Linum usitatissimum) seeds. CHEMBIOCHEM, 2001, 2, 45-51
  36. Łusiak M., Podwińska J., Żaba R.: IL-12 i jej rola w odporności przeciwkiłowej. Przegl. Dermatol., 2001, 3, 233-242
  37. Machoń Z., Wieczorek Z., Zimecki M.: Immunotropic activity of vratizolin (ITCL, Denotivir). Pol. J. Pharm., 2001, 53, 377-383 (IF-0.329)
  38. Majka J., Zakrzewska-Czerwińska J., Messer W.: Sequence recognition, cooperative interaction, and dimerization of the initiator protein DnaA of Streptomyces. J. Biol. Chem., 2001, 276, 6243-6252 (IF-7.199)
  39. Marcinkowska E.: Evidence that activation of MEK1,2/erk1,2 signal transduction pathway is necessary for calcitriol-induced differentiation of HL-60 cells. Anticancer Res., 2001, 21, 499-504 (IF-1.375)
  40. Marcinkowska E., Chrobak A., Więdłocha A.: Evading apoptosis by calcitriol-differentiated human leukemic HL-60 cells is not mediated by changes in CD95 receptor system but by increased sensitivity of these cells to insulin. Exp. Cell. Res., 2001, 270, 119-127 (IF-3.860)
  41. Matuszyk J., Kałas W., Cebrat M., Strządała L.: High expression of endogenous Bcl-2 and Bcl-xL in thymic lymphomas do not diminish their sensitivity to etoposide-induced apoptosis. Anticancer Res., 2001, 21, 2677-2680 (IF-1.375)
  42. Meisel-Mikołajczyk F., Rokosz A., Kot K., Zawidzka E., Malchar C., Nowaczyk M., Górski A.: Wpływ metronidazolu na stymulację ekspresji cząsteczek adhezyjnych na powierzchni komórek śródbłonka naczyniowego przez endotoksyny i enterotoksynę pałeczek Bacteroides fragilis. Med. Dośw. Mikrobiol., 2001, 53, 53
  43. Meisel-Mikołajczyk F., Rokosz A., Kot K., Zawidzka E., Malchar C., Nowaczyk M., Górski A.: Wpływ klindamycyny na stymulację wytwarzania cząsteczek adhezyjnych na powierzchni komórek śródbłonka naczyniowego przez endotoksyny i enterotokzynę pałeczek Bacteroides fragilis. Med. Dośw. Mikrobiol., 2001, 53, 151
  44. Messer W., Blaesing F., Jakimowicz D., Krause M., Majka J., Nardmann J., Schaper S., Seitz H., Speck Ch., Weigel Ch., Węgrzyn G., Welzeck M., Zakrzewska-Czerwińska J.: Bacterial replication initiator DnaA. Rules for DnaA binding and roles of DnaA in origin unwinding and helicase loading. Biochimie, 2001, 83, 1-9 (IF-1.617)
  45. Mielnik G., Gamian A., Doroszkiewicz W.: Bactericidal activity of normal cord serum (NCS) against Gram-negative rods with sialic acid-containing lipopolysaccharide (LPS). FEMS Immunol. Med. Microbiol., 2001, 31, 169-173 (IF-1.075)
  46. Mielnik G., Korzeniowska-Kowal A., Gamian A., Doroszkiewicz W.: Lipopolisacharydy zawierające kwas sjalowy a wrażliwość bakterii na bakteriobójcze działanie surowicy ludzkiej (NSL), Materiały IV Konferencji „Biologia molekularna w diagnostyce chorób zakaźnych i biotechnologii”, Wyd. SGGW, 139-141.
  47. Międzybrodzki R., Jędryka M., Goluda M., Fortuna W., Szymaniec S.: VEGF, TNF-alpha i IL-6 w płynie otrzewnowym kobiet z niepłodnością niejasnego pochodzenia. Ginekol. Pol., 2001, 73(5), 427-430
  48. Misiura K., Kinas R.W., Kuśnierczyk H., Radzikowski C., Stec W.J.: (S)-(-)-bromofosfamide (CBM-11): Synthesis and antitumor activity and toxicity in mice. Anti-Cancer Drugs, 2001, 12, 453-458 (IF-1.570)
  49. Misiura K., Kardacka K., Kuśnierczyk H.: Synthesis, in vitro metabolic studies, and antitumor activity of methyl analogues of ifosfamide. Arch. Pharm. Pharm. Med. Chem., 2001, 334, 291-294
  50. Misiura K, Szymanowicz D, Kuśnierczyk H.: Synthesis, chemical and enzymatic reactivity, and toxicity of dithymidylyl-3',5'-phosphorofluoridate and phosphorothio-fluoridate. Bioorg. Med. Chem., 2001, 9, 1525-1532 (IF-1.799)
  51. Nawrocka W., Sztuba B., Opolski A., Wietrzyk J., Kowalska M.W., Głowiak T.: Synthesis and antiproliferative activity in vitro of novel 1,5-benzodiazepines. Part II. Arch. Pharm. Pharm. Med. Chem., 2001, 334, 3-10 (IF-0.923)
  52. Nawrocka W., Sztuba B., Zimecki M.: Synthesis and immunotropic properties of 5-substi-tuted 1,5-benzodiazepin-2-ones derivatives in cultures of human peripheral blood cells, Part III. Arch. Pharm. Pharm. Med. Chem., 2001, 334, 11-16 (IF-0.923)
  53. Nowak I., Pochroń B., Kozłowska A., Dubis J., Kuśnierczyk P.: Effect of IFNg on expression of HLA on bare lyphocyte syndrome-like cell line HAJ. Arch. Immunol. Ther. Exp., 2001, 49, 453-460
  54. Novik G. I., Astapowicz N.I., Gamian A., Kübler-Kiełb J.: Polisacharydy Bifidobacterium adolescentis 94-BIM wykazujące efekty bifidogenne. Materiały Międzynarodowej Konferencji pt.: “Polityka zdrowego żywienia w Republice Białoruskiej”, Mińsk, 2001, 262-265.
  55. Osajda M., Kloc K., Młochowski J., Piasecki E., Rybka K.: Bisbenzisoselenazol-3(2H)-ones, a new group of ebselen analogues. Pol. J. Chem., 2001, 75, 823-830 (IF-0.575)
  56. Oszczapowicz I., Wąsowska M., Wietrzyk J., Oszczapowicz J., Opolski A.: Relationship between the structure of new anthracycline antibiotics and their ability to overcome drug resistance of cancer cells. J. Antimicrobial Chemiother, 2001, 17 (suppl. 1) S20 (IF-2.964)
  57. Palus J., Kloc K., Młochowski J., Małysa P., Szczurek M., Piasecki E., Rybka K.: Synthesis of 2,2’-diselenobisbenzamides and 4,4’-diselenobisbutyramides with sulfamoyl groups as new potential virucides and cytokine inducers. Pol. J. Chem., 2001, 75, 657-662 (IF-0,575)
  58. Palus J., Piasecki E., Rybka K.: Selenium-containing sulfonamides and related compounds as potential virucides; synthesis and properties. Ann. Pol. Chem. Soc., 2001, S6-A15
  59. Pałczyński B., Chełmońska-Soyta A., Zimecki M., Banach E.: IL-6 i TNF-a w hodowlach błony śluzowej jajowodów po stymulacji lipopolisacharydem (LPS) Escherichia coli. Ginekol. Pol., 2001, 72, 1334-1339
  60. Pączek L., Czarkowska-Pączek B., Korczak-Kowalska G., Wierzbicki P., Bartłomiejczyk I., Górski A.: Involvement of b2-microglobulin in CD69 expression on T cells. Arch. Immunol. Ther. Exp., 2001, 49, 239-242
  61. Popik P., Galoch Z., Janusz M., Lisowski J., Vetulani J.: Cognitive effects of colostral-Val nonapeptide in aged rats. Behavioural Brain Res., 2001, 118, 201-208 (IF–2.796)
  62. Poręba K., Opolski A., Wietrzyk J., Kowalska M.: Synthesis and antiproliferative activity in vitro of new derivatives of 3-aminopyrazolo[3,4-b]pyridine. Part I. Reaction of 3-aminopyrazolo[3,4-b]pyridine with 1,3-1,4-diketones and a,ß-unsaturated ketones. Arch. Pharm. (Weinheim), 2001, 334, 219-223 (IF-0.923)
  63. Pruchnik F.P., Starosta R., Ciunik Z., Opolski A., Wietrzyk J., Wojdat E., Duś D.: Tetraacetatodirhodium(II) complexes with tris(methoxyphenyl)phosphines, their reactivity, structure, and antitumor activity. Can. J. Chem., 2001, 79, 1-10 (IF-1.050)
  64. Rokosz A., Meisel-Mikołajczyk F., Kot K., Mieszała M., Szponar B., Gamian A.: Analiza kwasów tłuszczowych występujących w lipopolisacharydach Bacterioides thetaio-taomicron i Bacteroides fragilis. Med. Dośw. Mikrobiol., 2001, 53, 177-183
  65. Rokosz A., Meisel-Mikolajczyk F., Malchar C., Kot K., Zawidzka E., Nowaczyk M., Górski A.: Przyleganie ludzkich granulocytów i limfocytów T do komórek śródbłonka naczyniowego po stymulacji endotoksyną i enterotoksyną. Bacteroides fragilis. Med. Dośw. Mikrobiol., 2001, 53, 259
  66. Różalska M., Weber-Dąbrowska B., Józefowicz-Korczyńska M.: Kolonizacja ran pooperacyjnych endogennymi pałeczkami Gram-ujemnymi u pacjentów po chirurgicznym usunięciu raka krtani. Med. Dośw. Mikrobiol., 2001, 53, 197-206
  67. Ruchała P., Picur B., Wieczorek Z., Siemion I.Z.: 4-amino-N-methylproline isomers as the mimetics of dipeptide moiety with cis-amide bond. Peptides. Proceedings of the Twenty-Sixth European Peptide Symposium, September 10-15, 2000, Montpellier, France; Editions Medicales et Scientifiques, Paris 2001, p. 843-844
  68. Ryng S., Zimecki M., Fedorowicz A., Jezierska A.: Reactions of 5-amino-3-methyl-isoxazole-4-carboxylic acid hydrazide with carbonyl compounds: immunological activity and QSAR studies of products. Arch. Pharm. Pharm. Med. Chem., 2001, 334, 71-78 (IF-0.923)
  69. Saleh Y., Ziółkowski P., Rybka J., Siewiński M.: The combined treatment of transplantable solid mammary carcinoma in Wister rats by use of photodynamic therapy and cysteine proteinase inhibitor. In Vivo, 2001, 15, 351-358 (IF-0.704)
  70. Sikorska A., Traczyk Z., Konopka L., Fiszer-Maliszewska Ł., Wojciechowska B., Pińkowska-Grela B., Rygier J., Woroniecka R., Witkowska A., Rusin M.: Family with a Li-Fraumeni syndrome and no evidence of a germline mutation of the p53 gene or chromosomal abberations. J. Appl. Genet., 2001, 42(3), 379-384
  71. Siwińska A., Opolski A., Chrobak A., Wietrzyk J., Wojdat E., Kutner A., Szelejewski W., Radzikowski C.: Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D. Anticancer Res., 2001, 21, 1925-1929 (IF-1.375)
  72. Stefanowicz P., Boratyński J., Kańska U., Petry J., Szewczuk Z.: Evaluation of high temperature glycation of proteins and peptides by electrospray ionization mass spectrometry. Acta Biochim. Pol., 2001, 48(4), 1137-1142, (IF-0.749)
  73. Szewczuk Z., Buczek P., Stefanowicz P., Krajewski K., Siemion I.Z., Wieczorek Z.: Immunosuppressory activity of the cyclodimeric peptide with RGD sequences. Acta Biochim. Pol., 2001, 48(1), 121-130 (IF-0.749)
  74. Szewczuk Z., Wilczyński A., Gubernator J., Siemion I.Z., Wieczorek Z.: Immunosuppressory activity of ubiquitin fragments containing retro-RGD sequences. Peptides. Proceedings of the Twenty-Sixth European peptide Symposium, September 10-15, 2000, Montpellier, France: Editions Medicales et Scientifiques, Paris 2001, p. 751-752
  75. Szewczuk Z., Wilczyński A., Petry I., Siemion I.Z., Wieczorek Z.: Design, synthesis and biological evaluation of a new bridged immunosuppressor. Acta Biochim. Pol., 2001, 48, 1147-1151 (IF-0.749)
  76. Terszowski G., Jankowski A., Hendriks W., Rolink A., Kisielow P.: Within the hemopoietic system, LAR phosphatase is a T cell lineage-specific adhesion receptor-like protein whose phosphatase activity appears dispensable for T cell development, repertoire selection and function. Eur. J. Immunol., 2001, 31, 832-840 (IF-5.240)
  77. Weber-Dąbrowska B., Mulczyk M., Górski A.: Bacteriophages therapy for infections in cancer patients. Clin. Appl. Immunol. Rev., 2001, 1, 131-134
  78. Wietrzyk J., Boratyński J., Grynkiewicz G., Ryczyński A., Radzikowski C., Opolski A.: Antiangiogenic and antitumour effects in vivo of genistein applied alone or combined with cyclophosphamide. Anticancer Res., 2001 21(6), 3893-3896 (IF-1.331)
  79. Wietrzyk J., Mazurkiewicz M., Radzikowski C., Opolski A.: The influence of genistein on the growth of experimental mouse mammary cancer 16/C and on the effectiveness of treatment with cyclophosphamide. Eur. J. Cancer, 2001, 37 (suppl. 6), S169 (IF-2.725)
  80. Wietrzyk J., Opolski A., Zimowska W., Laskowska A., Rayssiguier Y., Radzikowski C., Ugorski M., Mazur A.: Magnesium deficiency inhibits primary tumor growth but favors metastasis of transplantable mouse lung cancer (LL2). Magnesium Res., 2001, 14, 122 (IF-0.825)
  81. Wiśniewski M.Z., Głowiak T., Opolski A., Wietrzyk J.: Synthesis, characterization and antiproliferative activity of the Co(II), Ni(II), Cu(II), Pd(II) and Pt(II) complexes of 2-(4-thiazolyl) benzimidazole (thiabendazole). Metal Based Drugs, 2001, 8, 189-194
  82. Wołowiec D., Ciszak L., Kosmaczewska A., Boćko D., Teodorowska R., Kuliczkowski K., Frydecka I.: Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocy-tic leukemia. Haematologica, 2001, 86, 1299-1304 (IF-2.5)
  83. Woźniak E., Czarny A., Różycka-Roszak B., Kocięba M., Łuczyński J., Witek S.: Antimicrobial effects of N-methyl quaternary derivatives of 2-dimethylaminoethylesters of saturated fatty acids with different counterions on bacterial biofilm. Ed. Prof. H. Górecki, Czech-Pol Trade, Praha, Brussels, Stockholm. “Chemistry for Agriculture”, vol. 2, „Pollution control in agriculture and fertilizer industry”, 2001, 372-376.
  84. Zabłocka A., Janusz M., Rybka K., Wirkus-Romanowska I., Kupryszewski G., Lisowski J.: Cytokine-inducing activity of a proline-rich polypeptide complex (PRP) from ovine colostrum and its active nonapeptide fragment analogs. Eur. Cytokine Net. 2001, 12, 462-467 (IF-1.693)
  85. Zaczyńska E., Błach-Olszewska Z.: Effect of cyclosporine A on the non specific, innate antiviral immunity of mice. Arch. Immunol. Ther. Exp., 2001, 49, suppl. 1, S53-S57
  86. Zagulski T., Jarząbek Z., Zagulska A., Jaszczak M., Kochanowska I. E., Zimecki M.: Lactoferrin stimulates killing and clearance of bacteria but does not prevent mortality of diabetic mice. Arch. Immunol. Ther. Exp., 2001, 49, 431-438
  87. Zawilak A., Cebrat S., Mackiewicz P., Król-Hulewicz A., Jakimowicz D., Messer W., Gościniak G., Zakrzewska-Czerwińska J.: Identification of a putative chromosomal replication origin from Helicobacter pylori and its interaction with the initiator protein DnaA. Nucleic Acids Res., 2001, 29, 2251-2259 (IF-4.878)
  88. Zimecki M., Stępniak D., Szynol A. and Kruzel M.L.: Lactoferrin regulates proliferative response of human peripheral blood mononuclear cells to phytohemagglutinin and mixed lymphocyte reaction. Arch. Immunol. Ther. Exp., 2001, 49, 147-154
  89. Zimecki M., Wieczorek Z.: Differential patterns of cyclosporine A-induced inhibition of humoral and cellular immune responses to sheep erythrocytes in mice. Pol. J. Pharm., 2001, 53, 495-500 (IF-0.456)
  90. Zimecki M., Właszczyk A., Wojciechowski R., Dawiskiba J., Kruzel M.: Lactoferrin regulates the immune responses in post-surgical patients. Arch. Immunol. Ther. Exp., 2001, 49, 325-333

Prace przeglądowe opublikowane:

  1. Boćko D., Szechiński J.: Zaburzenia immunologiczne w przebiegu twardziny układowej. Klinika Nowa, 2001, 8, 1140-1143
  2. Bogunia-Kubik K.: Wytwarzanie cytokin przez komórki krwi obwodowej i pępowinowej – porównanie i próba wyjaśnienia istniejących różnic. Post. Hig. Med. Dośw., 2001, 55(5), 629-641
  3. Cebrat M., Strządała L.: Rola szlaku sygnałowego Wnt i białka APC w etiologii raka okrężnicy. Post. Hig. Med. Dośw., 2001, 55, 513-524
  4. Dąbrowska K., Buś R., Mazur A., Górski A., Weber-Dąbrowska B., Mulczyk M.: Możliwość genetycznej modyfikacji bakteriofagów dla celów terapeutycznych. Pol. Arch. Med. Wew., 2001, CV, 1, 85-90
  5. Dejda A., Gorczyca W.A.: Zmiany ewolucyjne układu fotorecepcyjnego szyszynki. Post. Biol. Kom., 2001, 28, 571-588
  6. Fortuna W.: Zespół Wiskotta-Aldricha – uszkodzenie genu WASP i jego konsekwencje. Przegląd Pediatryczny, 2001, 31(3), 180-185
  7. Frydecka I., Boćko D., Kosmaczewska A.: Molekularne mechanizmy aktywacji limfocytów T i ich zaburzenia w schorzeniach nowotworowych układu krwiotwórczego. Acta Hematol. Pol., 2001, 32, supl. 1, 63-67
  8. Górski A.: Industry support of researchers in universities and academic medical centers. JAMA, 2001, 18, 285, 2324 (IF-11.435)
  9. Górski A.: Conflict of interest and its significance in Science and Medicine: a view from Eastern Europe. Science and Engineering Ethics, 2001, 7, 307
  10. Górski A.: Konflikt interesów w nauce i medycynie. Sprawy Nauki, 2001, 7, 14-18
  11. Górski A.: Konflikt interesów. Tendencje do komercjalizacji w nauce i dydaktyce wymagają pilnych uregulowań administracyjno-prawnych. Forum Akademickie, 2001, maj, 1-5
  12. Górski A.: Konflikt interesów. Właściwe standardy bioetyczne mogą przyczynić się do poprawy finansowania nauki i medycyny. Forum Akademickie, 2001, luty, 1-4
  13. Hidri N., Farina C., Mordarska H., Szponar B., Paściak M., Grzegorzewicz A., Gamian A., Boiron P.: Nocardia i nokardiozy. Pneumonol. Alergol. Pol., 2001, 69, (11-12), 667-676
  14. Janusz M., Lisowski J.: Kompleks polipeptydowy bogaty w prolinę (PRP) - Colostrinina®. Właściwości immunomodulatorowe i możliwości zastosowania w chorobie Alzheimera. Rocznik Psychogeriatryczny, 2001, 4, 137-147
  15. Jerzak P., Górski A:. Rola układu odpornościowego w patogenezie miażdżycy. Pol. Arch. Med. Wew., 2001, 2, 73-79
  16. Kaczmarek P., Frydecka I.: Molekularne mechanizmy wczesnej fazy aktywacji limfocytów T. Adv. Clin. Exp. Med., 2001, 10, 429-436
  17. Kobiałka M., Gorczyca W.A.: Wpływ cGMP na funkcje komórek układu odpornościowego. Post. Hig. Med. Dośw., 2001, 55, 195-210
  18. Kocięba M.: Receptor mannozowy. Post. Hig. Med. Dośw., 2001, 55, 759-773
  19. Korzeniowska-Kowal A., Witkowska D., Gamian A.: Mimikra cząsteczkowa bakteryjnych antygenów polisacharydowych i jej rola w etiologii chorób infekcyjnych i autoimmunologicznych. Post. Hig. Med. Dośw., 2001, 55, 211-232
  20. Kosmaczewska A., Ciszak L., Boćko D., Frydecka I.: Expression and functional significance of CTLA-4, a negative regulator of T cell activation. Arch. Immunol. Ther. Exp., 2001, 49, 39-46
  21. Kosmaczewska A., Frydecka I., Ciszak L., Boćko D.: Struktura i biologia kompleksu receptora limfocytów T (TCR/CD3). Post. Biol. Komórki, 2001, 2, 163-181
  22. Łapinski Ł., Jerzak M., Górski A.: Znaczenie składników płynu otrzewnowego w immunopatogenezie endometriozy. Post. Hig. Med. Dośw., 2001, 55, 775-785
  23. Łusiak M., Podwińska J.: Interleukin 10 and its role in the regulation of the cell-mediated immune response in syphilis. Arch. Immunol. Ther. Exp., 2001, 49, 417-421
  24. Marcinkowska E.: A run for a membrane vitamin D receptor. Biol. Signals Recept, 2001, 10, 341-349 (IF-2.278)
  25. Mikulska J. E.: Noworodkowy receptor Fcg (FcRn) – struktura i funkcja. Post. Hig. Med. Dośw., 2001, 55, 487-511
  26. Nowak I.: W stronę szczepionek peptydowych. Przegląd-EUREKA, KBN, Warszawa, 2001, 9
  27. Opolski A., Wietrzyk J., Siwińska A., Radzikowski C.: Nowe analogi witaminy D3 wzmagają efekt przeciwnowotworowy in vitro doksorubicyny, cisplatyny i genisteiny. PAN Działalność Naukowa, wybrane zagadnienia, 2001, 12, 140-141
  28. Opolski A., Wietrzyk J.: Inhibitory neoangiogenezy w terapii przeciwnowotworowej. Post. Hig. Med. Dośw., 2001, 55, 369-385
  29. Podwińska J., Łusiak M.: Czynniki istotne dla odpowiedzi typu komórkowego i odporności przeciwkiłowej. The factors important for cell-mediated immune response and immunity in syphilis. Post. Derm. i Alergol., 2001, 18, 171-176.
  30. Szponar B., Larsson L.: Use of mass spectrometry for characterising microbial communities in bioaerosols. Ann. Agric. Environm. Med., 2001, 8, 1-7
  31. Targońska M., Kochanowska I., Ostrowski K., Górski A.: Osteoimmunologia: nowy kierunek badań nad związkami układu immunologicznego i kostnego. Pol. Arch. Med. Wewn., 2001, 5(5), 435-440
  32. Smoliński P.: Prospects for treatment of HIV1 viral infections. Case Rep. Clin. Pract. Rev., 2001, 2(4), 295-304
  33. Weber-Dąbrowska B., Mulczyk M., Górski A.: Zastosowanie bakteriofagów w leczeniu zakażeń bakteryjnych. Działalność Naukowa PAN, wybrane zagadnienia, 2001, 11, 138-140
  34. Wróblewska H., Gorczyca W.A.: Fosfodiesterazy cyklicznego GMP. Post. Hig. Med. Dośw., 2001, 55, 611-627
  35. Wysocki M., Jerzak M.: Rola przeciwciał antyfosfolipidowych w immunopatologii łożyska. Post. Hig. Med. Dośw., 2001, 55, 643-653
  36. Zawilak A., Zakrzewska-Czerwińska J.: Organizacja genomu Helicobacter pylori. Post. Hig. Med. Dośw., 2001, 55, 355-367
  37. Zabłocka A.: Współzależność układu immunologicznego i nerwowego. Post. Hig. Med. Dośw., 2001, 55, 3-15

Książki i rozdziały w książkach opublikowane:

  1. Czarny A., Woźniak E., Łusiak M., Weber-Dąbrowska B., Różycka-Roszak B., Łuczyński J., Witek S.: Aktywność przeciwbakteryjna i przeciwgrzybicza grupy estrów betainy i alkoholu dodecylowego. Wyd. pod redakcją prof. R. Zielińskiego “Czwartorzędowe sole amoniowe i ich zastosowanie w gospodarce”, Poznań 2001, 234-239.
  2. Duk M., Wu A.M., Lisowska E.: Lectin and anti-carbohydrate antibody assays using chemically modified ligands. Adv. Exp. Med. Biol., 491 (Molecular Immunology of Complex Carbohydrates), ed. Wu AM, Kluwer Academic/Plenum Publishers, 2001, 127-132 (IF-0.513)
  3. Górski A.: Leczenie immunosupresyjne.W: „ Zarys immunologii klinicznej”, red. M. Zembala i A. Górski, PZWL, 270-277, 2001
  4. Górski A.: Zaburzenia immunologiczne związane z procesami starzenia. W: „Zarys immunologii klinicznej”, red. M. Zembala i A. Górski, PZWL, 2001, 198-199
  5. Górski A., Kasprzycka M., Nowaczyk M., Wierzbicki P., Korczak-Kowalska G., Jerzak P., Kłosowska D., Ekiert A., Kłodos K.: Statins as immunomodulatory drugs. W „Progress in basic and clinical immunology”, eds. A. Mackiewicz, M. Kurpisz i J. Żeromski, Kluwer Academic/Plenum Publishers, New York, 2001, 283-288
  6. Górski A., Krotkiewski H., Zimecki M. (eds): „Autoimmunity”, 2001, 1-197, Kluwer Academic Publishers, Dordrecht, Holandia, 2001
  7. Górski A., Krotkiewski H., Zimecki M. (eds): „Inflammation”, 2001, 1-211, Kluwer Academic Publishers, Dordrecht, Holandia, 2001
  8. Jerzak M.: Schorzenia autoimmunizacyjne. Niepłodność. W: „Zarys immunologii klinicznej”, red. M. Zembala i A. Górski. PZWL, 2001, 144-147
  9. Jerzak M.: Immunologia ciąży. W: “Wstęp do immunologii klinicznej”, red. M. Nowaczyk i A. Górski: - skrypt dla studentów. Akademia Medyczna w Warszawie, 2001, 165-184
  10. Jerzak P.: Immunologia miażdżycy. W “Wstęp do immunologii klinicznej”, red. M. Nowaczyk i A. Górski- skrypt dla studentów. Akademia Medyczna w Warszawie, 2001, 111-125
  11. Lisowska E.: Antigenic properties of human glycophorins – an update. Adv. Exp. Med. Biol. 491 (Molecular Immunology of Complex Carbohydrates), ed. Wu AM, Kluwer Academic /Plenum Publishers, 2001, 155-169 125 (IF-0.513)
  12. Lisowska E., Duk M.: Red blood cell antigens responsible for inherited types of polyag-glutination . Adv. Exp. Med. Biol. 491 (Molecular Immunology of Complex Carbohy-drates), ed. Wu AM, Kluwer Academic/Plenum Publishers, 2001, 141-153 (IF-0.513)
  13. Nowakowska B.: Antygeny zgodności tkankowej. W: „Zarys immunologii klinicz-nej”, red. M. Zembali i A. Górskiego, PZWL 2001, 200-206
  14. Nowaczyk M i Górski A.:. Podstawy immunologii klinicznej – skrypt dla studentów, AM Warszawa, 2001